References
- Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–396.
- Jones RN, Packer RR. Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately-susceptible to third-generation cephalosporins. Antimicrob Agents Chemother 1982; 22: 985–9.
- Hooton TM, Blair AD, Turk M, Counts GW. Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics. Antimicrob Agents Chemother 1984; 26: 535–8.
- Katsu M, Saito A. New antimicrobial agents series XXXIV: isepamicin. Jpn J Antibiot 1989; 42: 543–66.
- Miller GH, Chiu PJS, Waitz JA. Biological activity of SCH 21420, the 1-N-S-a-hydroxy-β-aminopropionyl derivative of gentamicin. Br J Antibiot 1978; 31: 688–96.
- Nagabhushan TL, Cooper AB, Tsai H, Daniels PJL, Miller GH. The synthesis and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and l-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B. Br J Antibiot 1978; 31: 681–87.
- Jones RN, Barry AL, Fuchs PC. l-N-(S-3-amino-2-hydroxylpropionyl) gentamicin B (SCH 21421): a collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates. Curr Microbiol 1978; 1: 359–64.
- Neu HC, Fu KP. 1-N-HAPA gentamicin B, a new aminoglycoside active against gentamicin resistant isolates – activity compared to other aminoglycosides. J Antibiot 1978; 31: 385–93.
- Sanders CC, Sanders WE, Goering RV. In vitro studies with SCH 21420 and SCH 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci. Antimicrob Agents Chemother 1978; 14: 178–84.
- Guimaraes MA, Sage R, Noone P. The comparative activity of eleven aminocyclitol antibiotics against 773 aerobic gram-negative rods and staphylococci isolated from infected hospitalized patients. J Antimicrob Chemother 1985; 16: 555–61.
- Watanakunakorn C. Comparative in vitro activity of a semisynthetic derivative of gentamicin B (SCH 21420) and five other aminoglycosides. J Antibiot 1978; 31: 1063–64.
- Schafer F, Norden CW. Activity of amikacin, gentamicin and Schering 21420 when combined with carbenicillin or piperacillin against Pseudomonas aeruginosa. Chemotherapy 1982; 28: 253–6.
- Shiritani Y, Yamaji S, Aoki A., et al. Synergistic activity of isepamicin and beta-lactam antibiotics against Pseudo monas aeruginosa in vitro and in vivo. J Antibiot 1988; 41: 1591–9.
- National Committee for Clinical Laboratory Standards. Approved standard M7-A2. Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd edn. National Committee for Clinical Laboratory Standard, Villanova, PA, 1990.
- Barry AL, Thornsberry C, Jones RN, Gerlach EH. Interpretative standards for disk susceptibility tests with SCH21420 and amikacin. Antimicrob Agents Chemother 1980; 18: 616–21.
- Shibata K, Mita I, Shinoda Y, et al. General pharmacological studies on isepamicin sulfate (HAPA-B). J Antibiot 1987; 40: 145–69.
- Chow AW, Wong J, Bartlett KH, Shafran SD, Stiver HG. Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations. Antimi-crob Agents Chemother 1989; 33: 1368–72.
- Eliopoulos GM, Eliopoulos CT. Ciprofloxacin in combination with other antimicrobials. Am J Med 1989; 87 (Suppl 5A): 17S–22S.
- Thornsberry C, Barry AL, Jones RN, Baker CN, Badal RE, Packer RR. Comparison of in vitro activity of SCH 21420, a derivative of gentamicin B, with that of amikacin, gentamicin, netilmicin, sisomicin and tobramycin. Antimicrob Agents Chemother 1980; 18: 338–45.
- Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev 1988; 1: 139–56.